
Hematology
Latest News
Latest Videos

More News

The move was based on updated safety data from an FDA probe into the risk of hematologic malignancies in patients treated with eli-cel.

The hematologist/oncologist at the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania discussed updates to NCCN guidelines and research to pay attention to in hematologic malignancies.

Review top news and interview highlights from the week ending August 8, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The Prescription Drug User Fee Act goal date for the sBLA has been set for December 5, 2025.

The patient’s death was attributed to anti-CD52 monoclonal antibody ALLO-647 rather than to cema-cel itself.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending August 1, 2025.

Notably, the BLA resubmission was accepted with priority review and the PDUFA target action date has been set for January 10, 2026.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

In episode 5 of ImmunoLogic, Michael T. Lotze, MD, discusses the evolution and future of tumor-infiltrating lymphocyte therapies.

Review top news and interview highlights from the week ending July 25, 2025.

The therapy was approved based on findings of the pivotal phase 1b/2 FELIX clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope discussed unanswered questions with regard to DLBCL treatment sequencing.

Review top news and interview highlights from the week ending July 18, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending July 11, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Alexey Danilov, MD, PhD, discussed the importance of reassessing sequencing stratagems in the face of a growing toolbox of targeted therapies in DLBCL.

Review top news and interview highlights from the week ending July 4, 2025.

The FDA made the move with the view that the REMS are no longer necessary to ensure a favorable risk-benefit-ratio for the products and that dropping the requirement may increase accessibility to these therapies.

Tami John, MD, a clinical associate professor at Stanford Medicine, emphasized the need to build community among patients with TDT.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.